Dihydrocodeine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Dihydrocodeine

Examples of brand names: DHC Continus [DE]

ATC code: N02AA08

Main use (for orientation): Pain

Documented research summary

A case report describes hyperkinesia and discusses CBD as a theoretical amplifier. Without verified exposure details, this is not an established CBD pair finding.

Uncertainties and limitations

The hyperkinesia case full text was inaccessible during browser retrieval (PMC CAPTCHA, Europe PMC error, BMJ 403); additional central retrieval requested. No quantified cannabinoid effect.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Theoretical context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Theoretical plausibility; no verified clinical pair effect

Mechanism / drug context: Dihydrocodeine: CYP2D6/CYP3A/glucuronidation; opioid-related central effects.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Dihydrocodeine tartrate, Ennogen 120 mg prolonged-release tablets; single-ingredient preparation assessed instead of the automatically found Trezix combination. The drug itself is active.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0149]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: Dihydrocodeine 120 mg prolonged-release tablets – Summary of Product Characteristics [CA_L_D0149]

Source role [CA_P_31969414]: Open case context

Statement supported: Abstract: dihydrocodeine reaction, theoretical CBD explanation; exposure/causal role insufficiently verified.

Source: Hyperkinetic reaction to dihydrocodeine. [CA_P_31969414]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: Complete saved individual review, label assessment, literature screening, conclusion and uncertainties read. Original information selectively rechecked by section; no complete revalidation of all prescribing information or full texts claimed. Full text unreadable at PMC due to browser verification and at the publisher due to access restrictions; no circumvention.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[CA_L_D0149] Dihydrocodeine 120 mg prolonged-release tablets – Summary of Product Characteristics

Original source / bibliographic reference

Authors: Ennogen IP Ltd

Year: 2025

Source type: Approved SmPC

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_31969414] Hyperkinetic reaction to dihydrocodeine.

Original source / bibliographic reference

Authors: van Oppen JD, Patel N, Tarique A.

Year: 2020

Source type: Journal Article; Case Reports; case-report

DOI: 10.1136/bcr-2019-233264

PMID: 31969414

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[AUDIT_A_DHC_P7586928] Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans

Original source / bibliographic reference

Authors: Fromm MF; Hofmann U; Griese EU; Mikus G

Year: 1995

Source type: Original publication; type described in the audit

DOI: 10.1016/0009-9236(95)90049-7

PMID: 7586928

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[AUDIT_A_DHC_CYP] Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine

Original source / bibliographic reference

Authors: Kirkwood LC; Nation RL; Somogyi AA

Year: 1997

Source type: Original publication; type described in the audit

DOI: 10.1046/j.1365-2125.1997.t01-1-00626.x

PMID: 9431830

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[AUDIT_A_DHC_PK] Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing

Original source / bibliographic reference

Authors: Ammon S; Hofmann U; Griese EU; Gugeler N; Mikus G

Year: 1999

Source type: Original publication; type described in the audit

DOI: 10.1046/j.1365-2125.1999.00042.x

PMID: 10510141

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[V5C_HYDROCODONE_28931] Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog

Original source / bibliographic reference

Authors: Cone EJ; Darwin WD; Gorodetzky CW; Tan T

Year: 1978

Source type: Original comparative metabolism study

PMID: 28931

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[V5C_DHC_11254193] Evaluation of urinary dihydrocodeine excretion in human by gas chromatography-mass spectrometry

Original source / bibliographic reference

Authors: Balikova M; Maresova V; Habrdova V

Year: 2001

Source type: Original study of human urinary excretion

DOI: 10.1016/S0378-4347(00)00509-0

PMID: 11254193

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility